Contraception
Volume 79, Issue 1 , Pages 50-55 , January 2009

Prevalence of psychiatric disorders and premenstrual dysphoric symptoms in patients with experience of adverse mood during treatment with combined oral contraceptives

  • Birgitta Segebladh

      Affiliations

    • Department of Women's and Children's Health, University Hospital, Uppsala University, SE-751 85 Uppsala, Sweden
    • Corresponding Author InformationCorresponding author. Tel.: +46 18 611 57 64; fax: + 46 18 55 97 75.
    • Authors B. Segebladh and A. Borgström equally share first authorship of this study.
    • ,
  • Anna Borgström

      Affiliations

    • Department of Women's and Children's Health, University Hospital, Uppsala University, SE-751 85 Uppsala, Sweden
    • Authors B. Segebladh and A. Borgström equally share first authorship of this study.
    • ,
  • Viveca Odlind

      Affiliations

    • Department of Women's and Children's Health, University Hospital, Uppsala University, SE-751 85 Uppsala, Sweden
    • Medical Products Agency, 751 03 Uppsala, Sweden
    • ,
  • Marie Bixo

      Affiliations

    • Department of Clinical Science, Obstetrics and Gynecology, Umeå University, 901 85 Umeå, Sweden
    • ,
  • Inger Sundström-Poromaa

      Affiliations

    • Department of Women's and Children's Health, University Hospital, Uppsala University, SE-751 85 Uppsala, Sweden

Received 27 March 2008 ,Revised 1 August 2008 ,Accepted 1 August 2008.

References 

  1. Joffe H, Cohen LS, Harlow BL. Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am J Obstet Gynecol. 2003;189:1523–1530
  2. Oinonen KA, Mazmanian D. To what extent do oral contraceptives influence mood and affect?. J Affect Disord. 2002;70:229–240
  3. Robinson SA, Dowell M, Pedulla D, McCauley L. Do the emotional side-effects of hormonal contraceptives come from pharmacologic or psychological mechanisms?. Med Hypotheses. 2004;63:268–273
  4. Sanders SA, Graham CA, Bass JL, Bancroft J. A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. Contraception. 2001;64:51–58
  5. Ernst U, Baumgartner L, Bauer U, Janssen G. Improvement of quality of life in women using a low-dose desogestrel-containing contraceptive: results of an observational clinical evaluation. Eur J Contracept Reprod Health Care. 2002;7:238–243
  6. Larsson G, Blohm F, Sundell G, Andersch B, Milsom I. A longitudinal study of birth control and pregnancy outcome among women in a Swedish population. Contraception. 1997;56:9–16
  7. Cullberg J. Mood changes and menstrual symptoms with different gestagen/estrogen combinations. A double blind comparison with a placebo. Acta Psychiatr Scand Suppl. 1972;236(Suppl):1–86
  8. Backstrom T, Hansson-Malmstrom Y, Lindhe BA, Cavalli-Bjorkman B, Nordenstrom S. Oral contraceptives in premenstrual syndrome: a randomized comparison of triphasic and monophasic preparations. Contraception. 1992;46:253–268
  9. Sangthawan M, Taneepanichskul S. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms. Contraception. 2005;71:1–7
  10. Borgström A, Kask K, Gulinello M, Odlind V, Sundström-Poromaa I. Patients with adverse mood effects from combined oral contraceptives have lower levels of prepulse inhibition than healthy controls. Psychoneuroendocrinology. 2008;33:487–496
  11. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22–33
  12. Spielberger CD, Gorusch RL, Lushene RE. Manual for the State-Trait Anxiety Inventory. Palo Alto: Consulting Psychology Press; 1970;
  13. Sundstrom I, Nyberg S, Bixo M, Hammarback S, Backström T. Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen. Acta Obstet Gynecol Scand. 1999;78:891–899
  14. New guidelines released . Recommendations focus on diagnosis and treatment. AWHONN Lifelines. 2000;4:61–62
  15. Hammarback S, Backstrom T. A demographic study in subgroups of women seeking help for premenstrual syndrome. Acta Obstet Gynecol Scand. 1989;68:247–253
  16. Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005;106:492–501
  17. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005;72:414–421
  18. Kero A, Hogberg U, Lalos A. Contraceptive risk-taking in women and men facing legal abortion. Eur J Contracept Reprod Health Care. 2001;6:205–218

PII: S0010-7824(08)00401-0

doi: 10.1016/j.contraception.2008.08.001

Contraception
Volume 79, Issue 1 , Pages 50-55 , January 2009

Article Tools

* Image Usage & Resolution